Sorafenib is an Inhibitor of UGT1A1 but is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia

PURPOSE: Several case reports suggest sorafenib exposure and sorafenib-induced hyperbilirubinemia may be related to a (TA)(5/6/7) repeat polymorphism in UGT1A1*28. We hypothesized that sorafenib inhibits UGT1A1 and individuals carrying UGT1A1*28 and/or UGT1A9 variants experience greater sorafenib ex...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Peer, Cody J., Sissung, Tristan M., Kim, AeRang, Jain, Lokesh, Woo, Sukyung, Gardner, Erin R., Kirkland, C. Tyler, Troutman, Sarah M., English, Bevin C., Richardson, Emily D., Federspiel, Joel, Venzon, David, Dahut, William, Kohn, Elise, Kummar, Shivaani, Yarchoan, Robert, Giaccone, Giuseppe, Widemann, Brigitte, Figg, William D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6432766/
https://ncbi.nlm.nih.gov/pubmed/22307138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-2484
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados